Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Unusually-High Trading Volume – Still a Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw an uptick in trading volume on Wednesday . 5,162,483 shares were traded during trading, an increase of 301% from the previous session’s volume of 1,287,501 shares.The stock last traded at $11.3648 and had previously closed at $11.05.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BAYRY. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Zacks Research raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. Finally, DZ Bank raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 2.9%

The business has a fifty day moving average price of $11.28 and a two-hundred day moving average price of $11.04. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. The firm has a market capitalization of $44.68 billion, a price-to-earnings ratio of -17.76, a price-to-earnings-growth ratio of 3.57 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, equities analysts expect that Bayer Aktiengesellschaft will post 1.24 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.